Clinical Trial Update: ACZ885 in Type 1 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 trial ACZ885 (canakinumab) in type 1 diabetes mellitus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 1 Diabetes Mellitus

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Diabetes Type 1 | Phase 2 | Status: WITHDRAWN